Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Elekta AB (publ)
  6. News
  7. Summary
    EKTA B   SE0000163628

ELEKTA AB (PUBL)

(EKTA B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Elekta : GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices

07/23/2021 | 08:01am EDT

ATLANTA, July 23, 2021 - Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements. The cancer treatment devices will allow GenesisCare to continue to invest in the latest world-class technology while providing access to high-quality care to their patients throughout their U.S. centers.

"With Brachytherapy an essential part of the care pathway for many cancer patients, GenesisCare offers this treatment modality across more than [70] locations worldwide," said Dr. Alvaro Martinez, a leading radiation oncologist at a GenesisCare facility in Michigan, and recent recipient of the prestigious Marie-Curie Medal for his lifetime achievements.

"Brachytherapy is one of the most precise and cost-effective forms of radiotherapy. There are many proven benefits to patients, both on its own and in combination with external beam radiotherapy," he added.  "GenesisCare's partnership with Elekta makes it easier to improve access for cancer patients and to ensure we can deliver the highest standards of care possible." 

Flexitron is Elekta's high dose rate (HDR) afterloader, used in almost two-thirds of all brachytherapy centers worldwide in over 100 countries. The latest version of Flexitron, introduced in 2020, sets itself apart from conventional brachytherapy devices through its design, ensuring efficient, safe and effective treatments with fewer manual steps.

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO. "Our vision is to provide access to the best cancer care to patients, and GenesisCare is helping to fulfill this objective by offering high precision radiation therapy in many of its U.S. centers."

Learn more about Flexitron at elekta.com/flexitron.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: E.T.: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

About GenesisCare
Sydney-headquartered GenesisCare, is an Australian founded healthcare company. It is the world's largest provider of cancer treatment using radiotherapy - a major treatment option for cancer patients - and one of the largest integrated oncology companies. The organization provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials.   

Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 300 locations in the U.S., 38 locations in Australia, 14 in the U.K. and 21 in Spain, with more than 30 new centers under development.

With a growing research and trials program numbering more than 150 clinical trials, a Contract Research Organization and global innovation program across Precision Medicine and Novel Therapy, GenesisCare has an ambition to accelerate the roll out of new therapy to more patients in need in a more affordable way.

The organization employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and now the U.S. We also offer cardiology and sleep services at more than 80 locations across Australia.

Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings. For more information visit www.genesiscare.com.

https://news.cision.com/elekta/r/genesiscare-extends-u-s--brachytherapy-service-with-27-elekta-flexitron-treatment-devices,c3388776

https://mb.cision.com/Main/35/3388776/1447892.pdf

https://news.cision.com/elekta/i/elekta-flexitron-afterloader,c2938097

https://news.cision.com/elekta/i/flexitron-in-treatment-room,c2938098

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ELEKTA AB (PUBL)
09/02ELEKTA : acquires Turkish distributor to strengthen market position
AQ
09/02ELEKTA AB (OM : EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S.
CI
08/31ELEKTA : Unity MR-Linac featured in 72 abstracts at European radiation oncology congress
AQ
08/31Elekta Unity MR-Linac Featured in 72 Abstracts At European Radiation Oncology Congress
CI
08/26ELEKTA : Board announces establishment of philanthropic Elekta Foundation
AQ
08/26ELEKTA AB (PUBL) : Ex-dividend day for interim dividend
FA
08/25GLOBAL MARKETS LIVE : Kering, Delta Air Lines, Pfizer, Moderna, Sony...
08/25ELEKTA : Report from the Annual General Meeting 2021 in Elekta
AQ
08/25Elekta AB Approves Dividend, Payable on 1 September 2021 and on 3 March 2022
CI
08/25Elekta AB Resolves on Dividend into Two Payments, Payable on 1 September 2021 and on 3 ..
CI
More news
Financials
Sales 2022 14 887 M 1 713 M 1 713 M
Net income 2022 1 372 M 158 M 158 M
Net Debt 2022 857 M 98,6 M 98,6 M
P/E ratio 2022 28,6x
Yield 2022 2,06%
Capitalization 38 609 M 4 437 M 4 442 M
EV / Sales 2022 2,65x
EV / Sales 2023 2,43x
Nbr of Employees 4 000
Free-Float 93,8%
Chart ELEKTA AB (PUBL)
Duration : Period :
Elekta AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELEKTA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 102,60 SEK
Average target price 116,08 SEK
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Gustaf Salford President & Chief Executive Officer
John Adebńck Chief Financial Officer & Group Treasurer
Laurent Leksell Chairman
Steven Mark Wort Chief Operating Officer
Caroline Mofors Chief Compliance & Integrity Office, Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ELEKTA AB (PUBL)-8.51%4 525
THERMO FISHER SCIENTIFIC30.92%239 899
DANAHER CORPORATION46.08%231 660
INTUITIVE SURGICAL, INC.27.53%124 147
SIEMENS HEALTHINEERS AG42.12%78 408
EDWARDS LIFESCIENCES CORPORATION31.61%74 843